AU2020315642B2 - Cardiac sarcomere inhibitor oral formulations - Google Patents

Cardiac sarcomere inhibitor oral formulations

Info

Publication number
AU2020315642B2
AU2020315642B2 AU2020315642A AU2020315642A AU2020315642B2 AU 2020315642 B2 AU2020315642 B2 AU 2020315642B2 AU 2020315642 A AU2020315642 A AU 2020315642A AU 2020315642 A AU2020315642 A AU 2020315642A AU 2020315642 B2 AU2020315642 B2 AU 2020315642B2
Authority
AU
Australia
Prior art keywords
weight
granular
total core
intra
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020315642A
Other languages
English (en)
Other versions
AU2020315642A1 (en
Inventor
Chunsheng Qiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of AU2020315642A1 publication Critical patent/AU2020315642A1/en
Application granted granted Critical
Publication of AU2020315642B2 publication Critical patent/AU2020315642B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020315642A 2019-07-17 2020-07-16 Cardiac sarcomere inhibitor oral formulations Active AU2020315642B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962875358P 2019-07-17 2019-07-17
US62/875,358 2019-07-17
PCT/US2020/042389 WO2021011808A1 (en) 2019-07-17 2020-07-16 Cardiac sarcomere inhibitor oral formulations

Publications (2)

Publication Number Publication Date
AU2020315642A1 AU2020315642A1 (en) 2022-03-03
AU2020315642B2 true AU2020315642B2 (en) 2026-04-02

Family

ID=71995104

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020315642A Active AU2020315642B2 (en) 2019-07-17 2020-07-16 Cardiac sarcomere inhibitor oral formulations

Country Status (25)

Country Link
US (1) US20220265612A1 (https=)
EP (1) EP3999038B1 (https=)
JP (1) JP7623342B2 (https=)
KR (1) KR20220082804A (https=)
CN (1) CN114765954B (https=)
AU (1) AU2020315642B2 (https=)
BR (1) BR112022000495A2 (https=)
CA (1) CA3144972A1 (https=)
CL (1) CL2022000108A1 (https=)
DK (1) DK3999038T3 (https=)
ES (1) ES2974542T3 (https=)
FI (1) FI3999038T3 (https=)
HR (1) HRP20240200T1 (https=)
HU (1) HUE065712T2 (https=)
IL (1) IL289884B2 (https=)
LT (1) LT3999038T (https=)
MX (1) MX2022000708A (https=)
PH (1) PH12022550083A1 (https=)
PL (1) PL3999038T3 (https=)
PT (1) PT3999038T (https=)
RS (1) RS65302B1 (https=)
SI (1) SI3999038T1 (https=)
SM (1) SMT202400107T1 (https=)
TW (1) TW202519217A (https=)
WO (1) WO2021011808A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
PT4370116T (pt) 2021-07-16 2025-03-14 Cytokinetics Inc Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva
WO2024020468A1 (en) 2022-07-20 2024-01-25 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
EP4565230A1 (en) 2022-08-04 2025-06-11 Cytokinetics, Inc. Methods for treating obstructive hypertrophic cardiomyopathy
WO2024179422A1 (zh) * 2023-03-02 2024-09-06 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
US20250295639A1 (en) 2024-03-20 2025-09-25 Cytokinetics, Incorporated Methods for treating heart diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205234A1 (en) * 2013-06-21 2014-12-24 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
US20170096435A1 (en) * 2015-09-30 2017-04-06 Quartet Medicine, Inc. Sepiapterin reductase inhibitors
WO2019144041A1 (en) * 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007027855A2 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
NZ598744A (en) * 2009-09-18 2013-11-29 Sanofi Sa (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
US20130273096A1 (en) * 2011-10-05 2013-10-17 Bruce A. Daniels Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients
WO2013112804A1 (en) * 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20170087180A1 (en) * 2014-06-03 2017-03-30 Sulfagenix, Inc. Methods and compositions for treating nitric oxide deficiency disorders and related conditions
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205234A1 (en) * 2013-06-21 2014-12-24 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
US20170096435A1 (en) * 2015-09-30 2017-04-06 Quartet Medicine, Inc. Sepiapterin reductase inhibitors
WO2019144041A1 (en) * 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PHILIPSON D. J ET AL: "Emerging pharmacologic and structural therapies for hypertrophic cardiomyopathy", HEART FAIL. REV., KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 22, no. 6, 31 August 2017, pp. 879 - 888 *

Also Published As

Publication number Publication date
PH12022550083A1 (en) 2023-04-12
PL3999038T3 (pl) 2024-05-13
TW202116307A (zh) 2021-05-01
RS65302B1 (sr) 2024-04-30
IL289884B1 (en) 2025-09-01
IL289884A (en) 2022-03-01
MX2022000708A (es) 2022-02-23
BR112022000495A2 (pt) 2022-03-03
IL289884B2 (en) 2026-01-01
NZ784934A (en) 2025-03-28
US20220265612A1 (en) 2022-08-25
CL2022000108A1 (es) 2022-10-21
DK3999038T3 (da) 2024-03-18
KR20220082804A (ko) 2022-06-17
HRP20240200T1 (hr) 2024-04-26
FI3999038T3 (fi) 2024-02-21
EP3999038A1 (en) 2022-05-25
ES2974542T3 (es) 2024-06-27
TW202519217A (zh) 2025-05-16
PT3999038T (pt) 2024-03-14
AU2020315642A1 (en) 2022-03-03
CN114765954B (zh) 2024-01-02
JP7623342B2 (ja) 2025-01-28
JP2022542804A (ja) 2022-10-07
EP3999038B1 (en) 2024-01-10
LT3999038T (lt) 2024-03-25
SMT202400107T1 (it) 2024-05-14
WO2021011808A1 (en) 2021-01-21
HUE065712T2 (hu) 2024-06-28
CA3144972A1 (en) 2021-01-21
SI3999038T1 (sl) 2024-05-31
CN114765954A (zh) 2022-07-19

Similar Documents

Publication Publication Date Title
AU2020315642B2 (en) Cardiac sarcomere inhibitor oral formulations
EP3999180B1 (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
EP3999181B1 (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide
CN119998292A (zh) 5-(3,4-二氟苄基)-8-((1r,4r)-4-甲基环己基)-6,9-二氧代基-2,5,8-三氮杂螺[3.5]壬烷-2-甲醛的结晶形式
RU2823999C2 (ru) Пероральные композиции ингибиторов сердечного саркомера
TWI917329B (zh) 心臟肌小節抑制劑口服調配物
HK40077275A (en) Cardiac sarcomere inhibitor oral formulations
HK40077275B (zh) 心脏肌节抑制剂口服制剂
RU2846046C2 (ru) Полиморфы (r)-n-(5-(5-этил-1,2,4,-оксадиазол-3-ил)-2,3-дигидро-1н-инден-1-ил)-1-метил-1н-пиразол-4-карбоксамида
HK40076616A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
HK40075684A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide